Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pracinostat in Combination With Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)

NCT03848754 is registered in ClinicalTrials.gov with Medical College of Wisconsin as lead sponsor.

NCT NCT03848754
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03848754 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pracinostat in Combination With Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)
Lead sponsor
Medical College of Wisconsin
Phase
Phase 1
Overall status
Completed
Start date
May 24, 2019
Completion date
May 5, 2021
Enrollment
14 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed adult aml